drugset / Trial / NCT01182376

SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI

NCT01182376

Phase 3 Completed 33 enrolled University of Utah Sanofi · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary objective of this study is to demonstrate how dronedarone (Multaq®) may aid in the slowing of progression of left atrial and ventricular fibrosis in patients with atrial fibrillation as assessed by late gadolinium enhanced magnetic resonance imaging.

Timeline

Start
2010-11
Primary completion
2012-12
Completion
2012-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronedarone Small molecule

Indications